Pemetrexed in advanced non-small cell lung cancer

Expert Opinion on Drug Safety

Volumn 10, Issue 2, 2011, Pages 311-317

  Gridelli, Cesare ^a   Maione, Paolo ^a   Rossi, Antonio ^a   Bareschino, Maria Anna ^a   Schettino, Clorinda ^a   Sacco, Paola Claudia ^a   Zeppa, Rosario ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

chemotherapy; NSCLC; pemetrexed; safety

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; FOLIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO;

ADVANCED CANCER; ALOPECIA; ANEMIA; CLINICAL STUDY; DRUG MECHANISM; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 79952349208     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.553281     Document Type: Review

References (27)

1. Parkin DM, Bray F, Ferlay J, et al. Global statistics cancer, 2002. CA Cancer J Clin 2005;55:74-108
2. Ries LAG, Eisner MP, Kosary CL, editors, SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004. Available from: http://seer.cancer.gov/csr/1975-2001/
3. Sant M, Aareleid T, Berrino F. EUROCARE-3: survival of cancer patients diagnosed 1990-94′results and commentary. Ann Oncol 2003;14(Suppl 5):v61-v118
4. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006;24:4539-44 (Pubitemid 46630948)
5. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 2001;19:1734-42 (Pubitemid 32230875)
6. Maione P, Rossi A, Bareschino MA, et al. Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Pharmacother 2010. [Epub ahead of print]
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50 (Pubitemid 44917502)
8. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34
9. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67
10. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57
11. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
12. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8
13. Zhou C, Wu Y-L, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations [abstract LBA13]. 35 ESMO congress Milan; 8-12 October 2010
14. Shih C, Chen VJ, Gossetti LS, et al. LY231514, a pirrolo[2,3-d] pyrimidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 1997;57:1116-23
15. Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999;26(Suppl 6):68-73
16. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthetase. Cancer 2006;107:1589-96 (Pubitemid 44546920)
17. Scagliotti G, Monica V, Ceppi P, et al. Baseline thymidylate synthetase expression according to histological subtypes of nonsmall cell lung cancer [abstract 7521]. J Clin Oncol 2009;27(15S):387s
18. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52
19. Scagliotti G, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. J Clin Oncol 2008;26:3543-51
20. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-63
21. Gronberg BH, Bremnes R, Flotten O, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-24
22. Gridelli C, Maione P, Rossi A, et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early-second line? Oncologist 2009;14:137-47
23. Grossi F, Aita M, Follador A, et al. Sequential, alternating and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist 2007;12:451-64 (Pubitemid 46698723)
24. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009;374:1432-40
25. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97 (Pubitemid 41079796)
26. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract P2-328]. J Thorac Oncol 2007;2(Suppl 4):S851
27. Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-11 (Pubitemid 46630978)